A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), ...

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...